The efficacy of E.P.D., a new immunotherapy, in the treatment of allergic diseases in children.
Allerg Immunol (Paris)
; 28(9): 308-10, 1996 Nov.
Article
en En
| MEDLINE
| ID: mdl-8986246
ABSTRACT
A double blind study was made on a group of 35 children, 8 of whom were allergic to Grass and 27 allergic to Pteronyssinus and Farinae Dermatophagoides. We verified the efficacy and tolerability of a new immunotherapy called E.P.D. (Enzyme Potentiated Desensitization). This particular immunotherapy consists in an intradermal injection of a mix made up of an allergic solution at extremely low doses and an enzyme, beta-glucuronidase. The vaccine is administered once a year, two weeks before pollen peaks for children with seasonal allergies and two times a year, in February and November, for children with non-seasonal allergies (Dermatophagoides). The results, statistically analyzed on the basis of a symptoms score, showed good clinical efficacy in patients affected by both seasonal and non-seasonal allergies. Due to the clinical effectiveness, easy administration and excellent tolerability of the immunotherapy, E.P.D. is particularly suited for treating or reducing allergic symptoms in allergic children.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Asma
/
Conjuntivitis Alérgica
/
Alérgenos
/
Rinitis Alérgica Perenne
/
Rinitis Alérgica Estacional
/
Desensibilización Inmunológica
Tipo de estudio:
Clinical_trials
/
Etiology_studies
Idioma:
En
Revista:
Allerg Immunol (Paris)
Año:
1996
Tipo del documento:
Article
País de afiliación:
Italia